As was previously noted, TP53 mutations in low and intermediate grade endometrioid carcinomas have been associated with reduced survival [22], and studies of endometrial cancer cell lines have showed that TP53 mutation increases invasion and migration, and therefore likely promote metastases [40]. This evidence concerns the gene TP53 and endometrioid adenocarcinoma.